PhD
Kenan Distinguished Professor and Chair, Department of Pharmacology
Co-Leader, UNC Lineberger Molecular Therapeutics Research Program
UNC-Chapel Hill
Molecular Therapeutics
Area of Interest
As a translational basic scientist, my research interests focus on understanding the behavior of the kinome en masse in cancer. My laboratory has developed chemical proteomics methods that allows measurement of the functional state of ~90% of the kinome that can be applied to cell lines, preclinical animal models, patient-derived xenografts and clinical trials. My laboratory integrates kinome proteomics with next generation sequencing and chromatin epigenetics to define the dynamic behavior and function of the kinome at both baseline and with perturbation. Our focus is on defining mechanisms of resistance to targeted kinase inhibitors.
Awards and Honors
- Hyman L. Battle Distinguished Cancer Research Award, UNC-Chapel Hill, 2017
News and Stories
Yeh, Johnson awarded five-year, $3.2 million research grant from NCI
The grant will support the first metastatic pancreatic cancer trial in the country to evaluate whether selecting treatment by tumor subtype will help patients match to more effective first-line therapies.
Getting to the heart of chemotherapeutic cardiotoxicity
Brian Jensen, MD, sees cancer patients who have developed, or are at risk of developing, heart damage in response to their chemotherapy regimens.
